ABSTRACT
Radiolabeled agent development has the flexibility to pursue functional or nonfunctional targets as long as they play a role in the specific disease or mechanism of interest and meet image ability requirements. Radiolabeled tracer development and application can provide nondestructive imaging information, allowing time-related phenomena to be repeatedly studied in a single animal. Radioisotopes with unnecessarily long half-lives should be avoided in order to limit the dose received by the patient. For therapy applications and in order to destroy tumor cells by mAbs, several mechanisms are available: via effector cells or complement-dependent cytotoxicity or through conjugation of the mAb to toxins, drugs, or radioisotopes. The radiolabeled diabody presented favorable properties required for further development for antibody-based imaging of PSMA expression in prostate cancer. The peptide synthesis and development is relatively cheap and can be performed quickly with automated synthesis units. Identification of the molecular target (receptor) using receptor autoradiography or immunohistochemistry.
